Abstract
BackgroundEconomic considerations increasingly play a role in the selection of antidepressant drugs and are often based on analyses from prospective and retrospective studies. However, the non-randomisation found in retrospective studies may result in significant selection bias.AimsTo highlight the use of statistical methods in non-randomised studies and the application of those methods to economic analyses.MethodThe literature on the observational studies of economic outcomes with alternative antidepressants is reviewed and several statistical methodologies to control for biases that can occur in non-randomised study designs are described.ResultsIn comparisons of antidepressant drugs, differences in acquisition costs are consistently found to be at least offset by other components of care when broad measures of health care resource utilisation are considered.ConclusionsEconomic evaluations of antidepressants should be based on broad measures of health care expenditure and can rely on data generated in real-world settings if appropriate statistical methods are used to control for the potential biases of non-randomisation.
Publisher
Royal College of Psychiatrists
Subject
Psychiatry and Mental health
Reference46 articles.
1. Fluoxetine and dothiepin therapy in primary care and health resource utilization: Evidence from the United Kingdom
2. Antidepressant pharmacotherapy: effect on women's resource utilization within a health maintenance organization;Skaer;Applied Therapeutics,1996
3. A cost-effective approach to the use of selective serotonin reuptake inhibitors in aVeterans Affairs Medical Center;Singletary;American Journal of Managed Care,1997
4. Cost-effectiveness comparisons using “real world” randomized trials: The case of new antidepressant drugs
5. Cost Implications of Initial Antidepressant Selection in Primary Care
Cited by
9 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献